MOUNTAIN VIEW, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2012 after the Nasdaq Market closes on Monday, February 25, 2013. The company will conduct a conference call and an audio webcast at 4:30pm EST the same day.

Date: February 25, 2013
Time:  4:30 PM EST

Listen via Internet: http://ir.vivus.com/

U.S. Toll-free:  877-359-2916
Outside U.S.:  (+) 224-357-2386

A webcast replay will be available on the VIVUS website for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company commercializing innovative therapies to address unmet needs in obesity and sexual health for U.S., Europe and other world markets. Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2011, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer


Financial Media Relations:
Joele Frank, Wilkinson Brimmer Katcher
Eric Bonach

212-355-4449

Investor Relations:
The Trout Group
Brian Korb

646-378-2923